Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has scheduled a conference call for 5th November 2020 at 8:00 AM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.agios.com
Earnings Expectation
Agios Pharmaceuticals, Inc. is reporting third quarter financial results on Thursday 5th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, AGIO is expected to report 3Q20 loss of $ 1.38 per share from revenue of $ 38.02 million.
For the full year, analysts anticipate top line of $ 204.84 million, while looking forward to loss of $ 4.72 per share bottom line.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors.
